Tumor lysis syndrome: Pathophysiology, definition, and alternative treatment approaches

Clinical Advances in Hematology and Oncology

Volumn 3, Issue 1, 2005, Pages 54-61

  Del Toro, Gustavo ^a   Morris, Erin ^a   Cairo, Mitchell S ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

Allopurinol; Cairo and Bishop classification system; Dialysis; Hyperkalemia; Hypocalcemia; Rasburicase; Tumor lysis syndrome; Urate oxidase; Urinary alkalinization

Indexed keywords

ACETAZOLAMIDE; ALLOPURINOL; ALUMINUM HYDROXIDE; ANTICONVULSIVE AGENT; BICARBONATE; CALCIUM; CREATININE; CYTOTOXIC AGENT; DIURETIC AGENT; DOPAMINE; FUROSEMIDE; GLUCONATE CALCIUM; GLUCOSE; INSULIN; MANNITOL; MERCAPTOPURINE; PHOSPHORUS; POLYSTYRENESULFONATE SODIUM; POTASSIUM; PURINE; RASBURICASE; URATE OXIDASE; URIC ACID;

ACUTE KIDNEY FAILURE; ALKALINIZATION; ARTICLE; BRONCHOSPASM; CALCIUM BLOOD LEVEL; CLINICAL TRIAL; CREATININE BLOOD LEVEL; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; HEART ARRHYTHMIA; HEMATOLOGIC MALIGNANCY; HEMOLYTIC ANEMIA; HUMAN; HYPERKALEMIA; HYPERPHOSPHATEMIA; HYPERSENSITIVITY REACTION; HYPERURICEMIA; HYPOCALCEMIA; HYPOVOLEMIA; INCIDENCE; METABOLIC SYNDROME X; METHEMOGLOBINEMIA; NONHODGKIN LYMPHOMA; PATHOPHYSIOLOGY; PHOSPHATE BLOOD LEVEL; POTASSIUM BLOOD LEVEL; PURINE METABOLISM; SEIZURE; SUDDEN DEATH; TREATMENT PLANNING; TUMOR LYSIS SYNDROME; URIC ACID BLOOD LEVEL;

DIAGNOSIS, DIFFERENTIAL; HUMANS; NEOPLASMS; TERMINOLOGY; TUMOR LYSIS SYNDROME; URATE OXIDASE;

EID: 14044267600     PISSN: 15430790     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Cairo MS, Bishop M. Tumour lysis syndrome: new therapeutic strategies and classification. Br J Haematol. 2004;127(1):3-11.
2. Hande KR, Garrow GC. Acute tumor lysis syndrome in patients with high-grade non-Hodgkin's lymphoma [review]. Am J Med. 1993;94(2):133-139.
3. Kedar A, Grow W, Neiberger RE. Clinical versus laboratory tumor lysis syndrome in children with acute leukemia. Pediatr Hematol Oncol. 1995;12(2):129-134.
4. Razis E, Arlin ZA, Ahmed T, et al. Incidence and treatment of tumor lysis syndrome in patients with acute leukemia. Acta Haematol. 1994;91(4):171-174.
5. Tsokos GC, Balow JE, Spiegel RJ, Magrath IT. Renal and metabolic complications of undifferentiated and lymphoblastic lymphomas. Medicine (Baltimore). 1981;60(3):218-229.
6. Zigrossi P, Brustia M, Bobbio F, Campanini M. Flare and tumor lysis syndrome with atypical features after letrozole therapy in advanced breast cancer. A case report [review]. Ann Ital Med Int. 2001;16(2):112-117.
7. Hain RD, Rayner L, Weitzman S, Lorenzana A. Acute tumour lysis syndrome complicating treatment of stage IVS neuroblastoma in infants under six months old. Med Pediatr Oncol. 1994;23(2):136-139.
8. Sewani HH, Rabatin JT. Acute tumor lysis syndrome in a patient with mixed small cell and non-small cell tumor [review]. Mayo Clin Proc. 2002;77(7):722-728.
9. Pentheroudakis G, O'Neill VJ, Vasey P, Kaye SB. Spontaneous acute tumour lysis syndrome in patients with metastatic germ cell tumours. Report of two cases. Support Care Cancer. 2001;9(7):554-557.
10. Annemans L, Moeremans K, Lamotte M, et al. Incidence, medical resource utilisation and costs of hyperuricemia and tumour lysis syndrome in patients with acute leukaemia and non-Hodgkin's lymphoma in four European countries. Leuk Lymphoma. 2003;44(1):77-83.
11. Van den Berghe G. Purine and pyrimidine metabolism between millennia: what has been accomplished, what has to be done? Adv Exp Med Biol. 2000;486:1-4.
12. Navolanic PM, Pui CH, Larson RA, et al. Elitek-rasburicase: an effective means to prevent and treat hyperuricemia associated with tumor lysis syndrome, a Meeting Report, Dallas, Texas, January 2002. Leukemia. 2003;17(3):499-514.
13. Bishop MR, Cairo MS, Coccia PF. Tumor lysis syndrome. In: Abeloff MD, Armitage JO, Niederhuber JE, et al, eds. Clinical Oncology 3rd ed. Philadelphia, Pa: Churchill Livingstone; 2004-987-992.
14. Cohen LF, Balow JE, Magrath IT, Poplack DG, Ziegler JL. Acute tumor lysis syndrome. A review of 37 patients with Burkitt's lymphoma. Am J Med. 1980;68(4):486-491.
15. Wechsler DS, Kastan MB, Fivush BA. Resolution of nephrocalcinosis associated with tumor lysis syndrome. Pediatr Hematol Oncol. 1994;11(1):115-118.
16. Cairo MS. Prevention and treatment of hyperuricemia in hematological malignancies [review]. Clin Lymphoma. 2002;3(suppl 1):S26-S31.
17. Ribeiro RC, Pui CH. Recombinant urate oxidase for prevention of hyperuricemia and tumor lysis syndrome in lymphoid malignancies [review]. Clin Lymphoma. 2003;3(4):225-232.
18. Lynch RE, Kjellstrand CM, Coccia PF. Renal and metabolic complications of childhood non-Hodgkin's lymphoma [review]. Semin Oncol. 1977;4(3):325-334.
19. Schilsky RL. Renal and metabolic toxicities of cancer chemotherapy. Semin Oncol. 1982;9(1):75-83.
20. Andreoli SP, Clark JH, McGuire WA, Bergstern JM. Purine excretion during tumor lysis in children with acute lymphocytic leukemia receiving allopurinol: relationship to acute renal failure. J Pediatr. 1986;109(2)292-298.
21. Silverman P, Distelhorst CW. Metabolic emergencies in clinical oncology [review]. Semin Oncol. 1989;16(6):504-515.
22. Jones DP, Mahmoud H, Chesney RW. Tumor lysis syndrome: pathogenesis and management [review]. Pediatr Nephrol. 1995;9(2);206-212.
23. Pak CY, Waters O, Arnold L, Holt K, Cox C, Barilla D. Mechanism for calcium urolithiasis among patients with hyperuricosuria: supersaturation of urine with respect to monosodium urate. J Clin Invest. 1977;59(3):426-431.
24. Ten Harkel AD, Kist-Van Holthe JE, Van Weel M, Van der Vorst MM. Alkalinization and the tumor lysis syndrome. Med Pediatr Oncol. 1998;31(1):27-28.
25. Hande KR, Hixson CV, Chabner BA. Postchemotherapy purine excretion in lymphoma patients receiving allopurinol. Cancer Res. 1981;41(6)2273-2279.
26. Frei E 3rd, Bentzel CJ, Rieselbach R, Block JB. Renal complications of neoplastic disease. J Chron Dis. 1963;16:757-776.
27. Goldman SC, Holcenberg JS, Finklestein JZ, et al. A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis. Blood. 2001;97(10):2998-3003.
28. DeConti RC, Calabresi P. Use of allopurinol for prevention and control of hyperuricemia in patients with neoplastic disease. N Engl J Med. 1966;274(9):481-486.
29. Smalley RV, Guaspari A, Haase-Statz S et al, Anderson SA, Cederberg D, Hohneker JA. Allopurinol: intravenous use for prevention and treatment of hyperuricemia. J Clin Oncol. 2000;18(8):1758-1763.
30. Spector T. Inhibition of urate production by allopurinol. Biochem Pharmacol. 1977;26(5):355-358.
31. Pui CH, Mahmoud HH, Wiley JM, et al. Recombinant urate oxidase for the prophylaxis or treatment of hyperuricemia in patients with leukemia or lymphoma. J Clin Oncol. 2001;19(3)697-704.
32. Coiffier B, Mounier N, Bologna S, et al. Efficacy and safety of rasburicase (recombinant urate oxidase) for the prevention and treatment of hyperuricemia during induction chemotherapy of aggressive non-Hodgkin's lymphoma: results of the GRAAL1 (Groupe d'Etude des Lymphomes de l'Adulte Trial on Rasburicase Activity in Adult Lymphoma) study. J Clin Oncol. 2003;21(23):4402-4406.
33. Bessmertny O, Robitaille LM, Cairo MS. Rasburicase: a new approach for preventing and/or treating tumor lysis syndrome. Curr Pharmacol Des. In press.
34. Pui CH, Jeha S, Irwin D, Camitta B. Recombinant urate oxidase (rasburicase) in the prevention and treatment of malignancy-associated hyperuricemia in pediatric and adult patients: results of a compassionate-use trial. Leukemia. 2001;15(10):1505-1509.
35. Kelly KM, Lange B. Oncologic emergencies [review]. Pediatr Clin North Am. 1997;44(4)809-830.
36. Jeha S. Tumor lysis syndrome [review]. Semin Hematol. 2001;38(4 suppl 10):4-8.
37. Rheingold SR, Lange BJ. Oncologic emergencies. In: Pizzo PA, Poplack DG, eds. Principles and Practice of Pediatric Oncology. 4th ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2002: 1177-1204.